You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》大摩上調康方生物-B(09926.HK)目標價至30元 評級「增持」
阿思達克 07-04 10:09
摩根士丹利發表報告,表示康方生物-B(09926.HK)新藥開坦尼獲中國藥監局批准上市,時機早於市場預期的第三季,快過中國藥監局的最後談判限期;管理層指引,料新藥推出後,首十二個月銷量達10億元人民幣,該行則料今年銷量為4.78億元人民幣,明年則為15億元人民幣,包括3億元人民幣的仿單標示外銷量。 該藥物用於治療既往接受含鉑化療治療失敗的復發或轉移性宮頸癌患者,成為首個獲批上市的國產雙抗,也是全球首款PD-1/CTLA-4雙抗。 該行表示,將假設加權平均資金成本(WACC)由11%下調至10.5%,以反映行業情緒升溫及更成熟的管線組合,並將公司今年、明年及2024年總收入預測分別上調8.22億元人民幣、22.57億元人民幣及38.56億元人民幣。 大摩將康方生物目標價上調50%,由20元升至30元,維持其評級為「增持」。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account